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ABSTRACT 49 
Myotonic dystrophy type 1 (DM1) is a multisystem disorder, caused by expansion of a 50 
CTG trinucleotide repeat in the 3’-untranslated region of the DMPK gene. The repeat 51 
expansion is somatically unstable and tends to increase in length with time, contributing 52 
to disease progression. In some individuals, the repeat array is interrupted by variant 53 
repeats such as CCG and CGG, stabilising the expansion and often leading to milder 54 
symptoms. We have characterised three families, each including one person with variant 55 
repeats that had arisen de novo on paternal transmission of the repeat expansion. Two 56 
individuals were identified for screening due to an unusual result in the laboratory 57 
diagnostic test, and the third due to exceptionally mild symptoms. The presence of 58 
variant repeats in all three expanded alleles was confirmed by restriction digestion of 59 
small pool PCR products, and allele structures were determined by PacBio sequencing. 60 
Each was different, but all contained CCG repeats close to the 3’-end of the repeat 61 
expansion. All other family members had inherited pure CTG repeats. The variant 62 
repeat-containing alleles were more stable in the blood than pure alleles of similar 63 
length, which may in part account for the mild symptoms observed in all three 64 
individuals. This emphasises the importance of somatic instability as a disease 65 
mechanism in DM1. Further, since patients with variant repeats may have unusually 66 
mild symptoms, identification of these individuals has important implications for 67 
genetic counselling and for patient stratification in DM1 clinical trials. 68 
Key Words 69 
Myotonic dystrophy type 1, somatic instability, variant repeats, PacBio sequencing 70 
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INTRODUCTION 73 
Myotonic dystrophy type 1 (DM1) is a dominantly inherited, multisystem condition. 74 
Features include skeletal muscle weakness and myotonia, cardiac conduction 75 
abnormalities, frontal balding, ptosis, cataracts, excessive daytime somnolence and 76 
insulin resistance [1]. DM1 results from the expansion of a CTG trinucleotide repeat in 77 
the 3’-untranslated region of the DMPK gene, with pathogenic alleles ranging from 78 
around 50 to over 1,000 repeats [2-4]. Age at onset and severity of symptoms are highly 79 
variable, and there is a broad inverse correlation between expansion size and age at 80 
onset of symptoms [5-7].  81 
The expanded CTG tract is unstable in the germline, and intergenerational expansions 82 
account for the phenomenon of genetic anticipation [8]. Furthermore, the tract is 83 
genetically unstable in somatic cells. Somatic mutation is expansion-biased, and 84 
correlates inversely with age at onset of symptoms [9]. This confounds genotype-85 
phenotype studies, as Southern blotting of restriction digested genomic DNA fails to 86 
take account of the effect of age on repeat length distribution. Small-pool PCR (SP-87 
PCR) can resolve somatic mosaicism, enabling calculation of individual-specific 88 
mutation rates [10], and allowing estimation of progenitor allele length, which is the 89 
major determinant of age at disease onset [11]. 90 
In ~3 to 5% of DM1 patients, the CTG repeat expansion contains interruptions, which 91 
may include CCG, CTC or GGC motifs [12-14]. The presence of such variant repeats 92 
can affect the mutational dynamics of the expanded DM1 allele, with implications for 93 
the clinical phenotype. For example, the usual pattern of anticipation may be lost due to 94 
increased stability in the germline. The repeats may also be stabilised in the soma, and 95 
 4 
patients with variant repeats may exhibit delayed onset, unusually mild symptoms, or 96 
atypical patterns of symptoms [12-15].  97 
Variant repeats may also affect diagnostic testing for DM1. This is usually carried out 98 
by triplet primed PCR (TP-PCR) [16,17], in which variant repeats can affect primer 99 
binding, resulting an atypical appearance of the amplicon ladder. An additional test, 100 
such as TP-PCR from the opposite end of the repeat, or Southern blotting of restriction 101 
digested genomic DNA, is therefore recommended to avoid false negatives [17]. In the 102 
light of the apparent associations between variant repeats and both unusual TP-PCR 103 
results and atypical disease symptoms, we hypothesised that patients with variant 104 
repeats might be identifiable within our Scottish DM1 patient cohort on this basis.  105 
MATERIALS AND METHODS 106 
Patient identification and recruitment 107 
Scottish adults with DM1 were recruited as part of the ongoing Genetic Variation in 108 
Myotonic Dystrophy Study (DMGV). Ethical approval was obtained for recruitment of 109 
patients with DM1 from the four major clinical genetics centres in Scotland (Glasgow, 110 
Edinburgh, Aberdeen, Dundee; WOS REC 08/S0703/121). Patients were recruited from 111 
annual outpatient review appointments, provided whole blood samples for DNA 112 
extraction and completed a standardised symptom questionnaire. Written informed 113 
consent was obtained, allowing study team access to medical records. Additional 114 
written consent was obtained from DMGV14 for publication of data relating to 115 
chorionic villus sampling (CVS) and preimplantation genetic diagnosis (PGD).  116 
PCR amplification and Southern blotting of expanded DM1 alleles 117 
Small pool PCR amplification of the CTG repeats and Southern blotting was carried out 118 
essentially as described [18], using the flanking primers DM-C and DM-DR [19]. 119 
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Where necessary, PCRs were supplemented with 10% DMSO (Sigma-Aldrich UK) and 120 
the annealing temperature was reduced to 63.5°C. Expanded alleles were screened for 121 
AciI-sensitive variant repeats by digestion with AciI (New England Biolabs UK Ltd; 122 
restriction site 5’-CCGC-3’). When DMSO had been added to the PCRs, the amplicons 123 
were first purified using the QIAquick PCR purification kit (Qiagen UK). The probe 124 
used for Southern blotting was a PCR product with 56 CTGs amplified using DM-C and 125 
DM-DR. Repeat lengths were estimated using CLIQS 1D gel analysis software 126 
(TotalLab UK Ltd.) by comparison against the molecular weight marker. The lower 127 
boundary of the expanded alleles was used to estimate the inherited repeat length (the 128 
estimated progenitor allele length; ePAL) [19], the major determinant of age at onset of 129 
symptoms [11]. The densest point of the distribution of alleles was also used to estimate 130 
the modal allele length.  131 
Whole genome amplification of DNA extracted from single cells 132 
Single cells biopsied from a 3-day embryo were collected into PBS, lysed with 200 mM 133 
NaOH and 50 mM dithiothreitol at 65°C for 10 minutes, then neutralised using 200 mM 134 
tricine. Multiple displacement amplification was then carried out using the REPLI-g® 135 
kit (Qiagen). The appropriate amount of whole genome amplified (WGA) template for 136 
PCR was determined empirically by serial dilution. 137 
Library preparation for PacBio RS II sequencing 138 
Expanded DM1 alleles were sequenced using the PacBio RS II platform (Pacific 139 
Biosciences Inc.) [20]. Material for sequencing was generated by PCR using 250 ng 140 
genomic DNA template per patient. For each sample, a different, barcoded forward 141 
primer was used. These consisted of the forward flanking primer DM-C, with a 5’-end 142 
extension encoding an IonXpress™ barcode (Thermo Fisher Scientific UK). 143 
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Amplification conditions were as for non-barcoded primers. Amplicons were 144 
concentrated using 1.8X volume Agencourt® AMPure® XP beads (Beckman Coulter 145 
UK). The expanded alleles were excised from 1% agarose gels, based on prior estimates 146 
of the range of allele lengths obtained by SP-PCR. Amplicons were purified using the 147 
QIAquick gel extraction kit (Qiagen UK), quantified using the Qubit® dsDNA HS 148 
assay kit (Thermo Fisher Scientific UK) and combined to form an equimolar pool, 149 
based on estimated modal allele lengths. The amplicon pool was concentrated further 150 
using 1.8X volume Agencourt® AMPure® XP beads, and eluted in 10 mM Tris, pH 151 
8.0. Generation of SMRTbell™ templates and subsequent sequencing were performed 152 
at the Human and Molecular Genetics Center, Medical College of Wisconsin, 153 
Milwaukee, WI, USA, or the Earlham Institute, Norwich, UK. Circular consensus 154 
sequence (CCS) reads [21] were generated at Milwaukee or Earlham using the CCS 155 
algorithm in the SMRT™ Portal provided by PacBio. 156 
Bioinformatic analysis  157 
PacBio sequence reads were analysed using open source tools on the Galaxy instance of 158 
Glasgow Polyomics, University of Glasgow [22,23]. CCS reads were demultiplexed by 159 
barcode using the Je-demultiplex tool [24], then mapped against DM1-specific 160 
reference sequences using BWA-MEM [25,26] and visualised using Tablet [27]. Since 161 
we had included a 5’-end barcode only, reverse and complement reads were also 162 
demultiplexed to increase the yield of sequence reads for each patient.  163 
Data from all subjects in the three families described have been deposited in the 164 
ClinVar database (https://www.ncbi.nlm.nih.gov/clinvar/). Accession numbers 165 
SCV000747869 to SCV000747879.  166 
 167 
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RESULTS 168 
Two hundred and fifty one adults with DM1 were recruited from annual review 169 
appointments. In three families (Fig 1), one individual was identified to be screened for 170 
variant repeats, because of an unusual TP-PCR trace or an unusual pattern of symptoms. 171 
In all cases, the individual identified for variant screening had been diagnosed with 172 
DM1 after requesting a genetic test in the context of a known family history of the 173 
condition. None was the index case in their family. All other members of the three 174 
families had classical DM1 symptoms, and nothing unusual was noted regarding their 175 
molecular diagnostic tests. Clinical summaries are provided in Table 1, with further 176 
detail in Supplementary data.  177 
Patient DMGV14 (Family 1, Fig 1) underwent predictive testing for DM1 at the age of 178 
18. TP-PCR from the 3’-flank of the CTG repeat [16] failed to detect an expansion, 179 
though Southern blot of restriction digested genomic DNA later confirmed the presence 180 
of an expanded allele. At age 27, bidirectional TP-PCR was undertaken in another 181 
diagnostic laboratory. This showed a typical ladder of peaks within the affected range 182 
on 5’-TP-PCR, but on 3’-TP-PCR a shorter ladder corresponding to ~50 CTG repeats 183 
and at a reduced intensity was seen (data not shown). At age 33, DMGV14 had no 184 
detectable muscle signs of DM1, and was in full-time employment in an office 185 
environment.  186 
DMGV182 (Family 2, Fig 1) requested genetic testing for DM1 at age 43. He denied 187 
DM1-specific symptoms, although volunteered a history of jaw discomfort and 188 
“slowness” on biting down. Bidirectional TP-PCR from the 3’-end detected ~60 repeats, 189 
whereas from the 5’-end, greater than 150 repeats were seen (data not shown). In view 190 
of the patient’s mild symptoms and atypical TP-PCR result, electromyography (EMG) 191 
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studies and an ophthalmic examination were requested. EMG showed no myotonia in 192 
peripheral muscles, though there was increased insertional activity suggestive of 193 
increased muscle membrane irritability. Mild myotonia was detected in masseter. 194 
Ophthalmic examination revealed bilateral early posterior subcapsular cataracts.  195 
DMGV15 (Family 3, Fig 1) underwent predictive testing for DM1 at age 22. She had 196 
not noted any muscle symptoms and had no typical DM1 features. Southern blot 197 
analysis of restriction digested genomic DNA confirmed the presence of a CTG repeat 198 
expansion. Bidirectional TP-PCR on blood DNA from DMGV15 gave a characteristic 199 
ladder consistent with an expanded repeat in the 5’-direction, and a ladder with reduced 200 
intensity in the 3’-direction (data not shown). An experienced nurse specialist (YR) 201 
noted the clinical discordance between DMGV15 and her classically affected brother, 202 
DMGV54, and suggested she be screened for variant repeats. At age 46, DMGV15 had 203 
no clear signs or symptoms of DM1, and was in full time employment.  204 
Blood DNA samples from all available members of the three families were PCR 205 
amplified using flanking DM1 primers. Amplicons were digested with AciI, to screen 206 
for CCG or CGG variant repeats. Both alleles from most individuals were amplified 207 
successfully (Fig 1), however in the case of DMGV14, the expanded allele only 208 
amplified in the presence of 10% DMSO, suggesting it has a particularly high G + C 209 
content, possibly indicative of variant repeats. In all three individuals with putative 210 
variant repeats (DMGV14, 182 and 15), the expanded allele amplicons digested with 211 
AciI. Those of all other family members remained undigested (Fig 1). These data 212 
suggest that in each of these three families, variant repeats have arisen de novo during 213 
paternal transmission of the repeat expansion. 214 
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Variant repeat interruptions may stabilise the repeat array, reducing the rate of repeat 215 
expansion over time [13]. In order to determine whether this is the case for DMGV14, 216 
182 and 15, SP-PCRs were compared against those from five DM1 patients of similar 217 
ePAL and age to the three variant repeat patients, but whose expanded alleles contain no 218 
AciI-sensitive variant repeats (data not shown) (Fig 2A). The ePAL and mode were 219 
determined for each patient (Table 2). The difference between the two measures 220 
(ΔCTG) may be used as a simple measure of somatic instability. The repeat length 221 
change for DMGV14, 182 and 15 is less than for any of the patients that lack variant 222 
repeats (Table 2, Fig 2A).  223 
DMGV14 has had in vitro fertilization and PGD. As part of the PGD protocol, a single 224 
cell was removed for DM1 testing. We obtained WGA material from these assays, and 225 
also genomic DNA from a previous CVS. In order to determine whether DMGV14’s 226 
expanded allele was stabilised in the germline, SP-PCR and AciI digestion were carried 227 
out (Fig 2B). From eight separate fertilisations, one expanded allele was approximately 228 
the same overall length as DMGV14’s, and the remaining seven were substantially 229 
longer, including one with over 1,300 repeats. All embryos also had a longer stretch of 230 
pure CTG repeats at the 5’-end than DMGV14.  231 
The expanded alleles from all available members of the three families were next 232 
sequenced using the PacBio RSII platform. Reads were aligned against a DM1 233 
reference sequence, comprising 600 CTG repeats and 72 bp of 3’-flanking sequence. 234 
The aligned reads from DMGV14, 15 and 182 contained CCG mismatches close to the 235 
3’-end of the CTG repeat expansion (Fig 3). Most [12-15], but not all [28,29], of the 236 
DM1 variant repeats characterised to date have been near the 3’-end of the repeat array. 237 
The 5’-ends of the variant repeat-containing reads, and the entire length of the reads 238 
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from all other family members, generally consisted of pure CTG repeats (Fig 3, Fig S2). 239 
However, each individual read might contain one or more sequence variants, including 240 
but not limited to CCG. These had no consistent pattern of distribution, and most likely 241 
resulted from a mixture of sporadic somatic variants and PCR and/or sequencing errors. 242 
A high percentage of reads from all patients also lacked a G residue in the immediate 243 
3’-flank (Fig 3, Fig S1, Fig S2), which most likely results from a common sequencing 244 
error, since it was not seen in Sanger sequenced, PCR amplified DM1 alleles (data not 245 
shown). It also appeared to be site-specific, as the mean percentage of reads missing a G 246 
was higher for data generated in Wisconsin (61%) than at Earlham (14.5%).  247 
Sequence reads from DMGV14 were aligned against the reference sequence described 248 
above. A large number of CCGCTG hexamers was present towards the 3’-end of the 249 
repeats (Fig 3). These were variable in number between reads, as was the number of 250 
CTG repeats at each end. Aligned reads (603 in total) were examined in detail to 251 
determine the consensus pattern of variant repeats as 252 
NM_004409.4(DMPK):c.*224_283CTG[180_240]CCGCTG[53_67]CTG[53_67]. (Fig 253 
3). This is broadly consistent with the AciI digestion, which generated AciI-resistant 254 
fragments equivalent to ~225 and ~70 CTG repeats (Fig 1). DNA from the WGA 255 
samples E1 and E2 was also sequenced, and these reads also contained CCGCTG 256 
hexamers close to the 3’-end (Fig S1). Assuming the expanded alleles from the CVS 257 
sample, and the WGA samples E3 to E7, also had CCGCTG hexamers near the 3’-end, 258 
allele structure was estimated for each (Fig S1) based on the AciI digestion experiment 259 
(Fig 2). Reads from the expanded alleles of DMGV14’s other family members 260 
DMGV165, DMGV83 and DMGV57, contained no germline CCG repeats (Fig 3, Fig 261 
S2).  262 
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When DMGV182’s reads were mapped against the reference sequence described above, 263 
CCG variant repeats were visible in a highly variable distribution close to the 3’-flank 264 
(Fig 3). Aligned reads (163 in total) were examined to determine the average allele 265 
structure. Many of these reads (~17%) contained no CCG repeats at all in the cluster 266 
near the 3’-end. Around 26% contained a single CCG, ~26% had two, ~26% had from 3 267 
to 9 CCGs separated by one or more CTG repeats, and ~4% contained from 6 to 26 268 
consecutive CCG repeats (Fig 3). The average structure of the reads is broadly 269 
consistent with the AciI digestion, where AciI-resistant fragments corresponding to 270 
~245 CTG and ~60 CTG repeats were generated (Fig 1). Sequence reads from the other 271 
family members, DMGV234, 184 and 242 showed no evidence of germline CCG 272 
variant repeats (Fig 3, Fig S2), consistent with the AciI digestion (Fig 1).  273 
Around 17% of the aligned PacBio sequence reads from DMGV182 appear to contain 274 
no variant repeats in the cluster near the 3’-flank, a much higher percentage than for 275 
DMGV14 (<1%). To test whether PCR and/or sequencing errors are responsible for the 276 
high percentage of sequence reads that lack CCGs, a single molecule AciI digestion 277 
experiment was performed. Multiple reactions using from 7.5 to 50 pg template per 278 
reaction were carried out, digested with AciI, blotted and hybridised as before, 279 
generating 215 distinct bands over several experiments. No undigested bands were seen. 280 
In ~30% of bands, complete digestion occurred, and ~70% of bands were only partially 281 
digested by AciI (Fig 4). This suggests that ~70% of individual bands blotted contain a 282 
mixture of molecules with and without AciI sites (Fig 4). From this result we infer that 283 
at least a single restriction site was present in DMGV182’s original germline allele. We 284 
therefore estimated the germline allele structure to be 285 
NM_004409.4(DMPK):c.*224_283CTG[200_300]CCG[1]CTG[41_59]. 286 
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 287 
When expanded alleles from DMGV15 were aligned against the reference sequence 288 
described above, a block of CCG(CTG)2 nonamer variant repeats was visible towards 289 
the 3’-end of the reads (Fig 3). For 338 aligned sequence reads, an average structure 290 
was determined as 291 
NM_004409.4(DMPK):c.*224_283CTG[260_320]CCGCTGCTG[10_14]CTG[15_23].292 
This is broadly consistent with the AciI digest, which generated an AciI-resistant 293 
fragment equivalent to ~245 CTG repeats. A second predicted 135 bp digestion-294 
resistant fragment may be hidden by the non-disease causing allele.  295 
All 251 individuals recruited to DMGV were screened for variant repeats by digestion 296 
with AciI. Eighteen individuals in total, including the three described here, had AciI 297 
sensitive variant repeats, giving an overall prevalence of 7.2%. This included seven 298 
apparently independent occurrences from a total of 169 families (4.1%). No other 299 
example of de novo gain of variant repeats has been identified to date in this cohort. 300 
DISCUSSION 301 
In this study, we have identified three DM1 patients with CCG variant repeats generated 302 
by apparent de novo mutations. The variant repeats appear to stabilise the expanded 303 
alleles in the blood, and all three patients have symptoms that are milder than expected. 304 
We also describe the first use of PacBio SMRT sequencing to study CTG repeat 305 
expansions in DM1. PacBio sequencing was previously used to sequence repeat 306 
expansions in the fragile X gene [30], and spinocerebellar ataxia types 10 [31,32] and 307 
31 [33]. We have now used this technology to characterise DM1 mutant allele structures 308 
in greater detail than was previously possible using cloned DNA fragments [12,13].  309 
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Our findings add further evidence for a major contribution of somatic instability to 310 
disease progression in DM1. We have previously shown that the principal genetic 311 
determinant of age at onset of symptoms in DM1 is the progenitor allele length, and that 312 
age at onset is further modified by individual-specific differences in the level of somatic 313 
instability [11]. Furthermore, somatic instability is greater in tissues most severely 314 
affected, for example skeletal muscle and cerebral white matter [34,35], suggesting 315 
tissue-specific differences in expansion rates may account in part for the pattern of 316 
symptoms. In the present three cases, reduced somatic expansion was accompanied by 317 
milder symptoms, consistent with somatic instability as a key driver of DM1 318 
pathophysiology.  319 
The major factors influencing somatic instability of expanded trinucleotide repeats are 320 
not currently fully understood, although there is evidence for a modifying effect of 321 
sequence variants in genes involved in DNA mismatch repair [36,37], as well as 322 
epigenetic changes at the repeat locus itself [38]. In other trinucleotide repeat disorders, 323 
variant repeat motifs have been described acting as ‘anchors’, reducing the likelihood of 324 
misalignment events during DNA processing [39,40]. Consistent with previous studies 325 
[13], our data suggest that in DM1 variant repeats have a comparatively major 326 
stabilising effect, also increasing the stability of the neighbouring pure CTG sequence.  327 
Other mechanisms have also been explored to account for milder symptoms associated 328 
with variant repeats in DM1. The primary cellular pathology in DM1 results from the 329 
toxicity of mRNAs that contain expanded CUG repeats. These repeats adopt a hairpin 330 
secondary structure [41], and sequester several key regulatory RNA-binding proteins, 331 
including muscleblind-like protein 1 (MBNL1), in the form of ribonuclear foci. 332 
Perturbations in the relative levels of different splicing factors lead to dysregulation of 333 
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alternative splicing of a range of key proteins (reviewed in [42]). Variant repeats within 334 
the CUG expansion may alter mRNA secondary structure, which may in turn affect 335 
affinity for effector proteins in the DM1 cascade [13]. In addition, a unique, highly 336 
polarised pattern of hypermethylation has been described in patients with variant repeats 337 
near the 3’-end of the array [43], which could affect local gene expression as well as 338 
influencing repeat instability. 339 
In all three cases we describe here, as well as a recently described de novo CTC variant 340 
repeat [15], the DM1 expansion was paternally inherited. While this may be due to 341 
chance, the larger number of cell divisions in male gametogenesis does markedly 342 
increase the chance of replication-associated errors [44]. In a previously reported family 343 
with inherited CCGCTG variant repeats, expansion of the variant hexamer within the 344 
repeat array was observed during paternal transmission [13]. It may therefore be the 345 
case that, a single de novo substitution having occurred sporadically, subsequent DNA 346 
processing errors in postpubertal spermatogenesis facilitated further expansion of the 347 
variant sequence to produce the larger blocks seen in families 1 and 3. 348 
In eight separate germline transmissions of DMGV14’s CCGCTG variant repeats, the 349 
pure CTG repeats at the 5’-end always expanded, and in most cases the overall allele 350 
length also increased, including one allele that had over 1,300 repeats. Although the 351 
necessary step of WGA could have introduced artefactual changes in the repeat, this 352 
seems unlikely, since all PCRs generated a single discrete band for the expanded allele. 353 
Furthermore, both the uncut and digested fragment lengths were concordant between 354 
trophectoderm and blastomere cells where both were available for a single embryo. The 355 
results contrast previously described germline transmissions of variant repeat-356 
containing alleles, where size increases after maternal transmission were only ~50 357 
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repeats [13], or where multiple intergenerational contractions occurred in a family 358 
[12,15]. While the phenotype that would be associated with the larger germline 359 
expansions of DMGV14’s allele cannot be predicted, this finding urges caution against 360 
counselling patients that variant repeats are unlikely to be associated with congenital 361 
onset DM1 on transmission. Characterisation of a greater number of variant repeat 362 
families is therefore a priority, to facilitate more accurate genetic counselling of affected 363 
individuals regarding implications for prospective pregnancy.  364 
DMGV182’s expanded allele was unusual in that ~17% of sequence reads contained no 365 
CCGs in the variant-containing zone near the 3’-end (Fig 3). However, in a single 366 
molecule SP-PCR and AciI digestion experiment, all bands were at least partially 367 
digested by AciI (Fig 4), suggesting there are no alleles that lack variant repeats. One 368 
possible explanation is that variant repeats were present in the genomic DNA template, 369 
but were sometimes lost during PCR. Partial digestion of a band might result from 370 
slipped-strand products with complementary loopouts disrupting the AciI cut site in 371 
some molecules (Fig S3). Slipped-strand DNA structures form in disease-associated 372 
triplet repeats [40,45], and have recently also been shown to occur in vitro during PCR 373 
amplification of DM1 alleles [46]. PCR slippage errors might also generate a subset of 374 
amplicons that have lost their variant repeats, and hence do not digest (Fig S3). The 375 
sequence reads that lacked CCG variant repeats may have been generated by PCR 376 
slippage errors, or by errors in the generation of ccs reads from the raw sequence data.  377 
The three cases described, of de novo variant repeats accompanied by mild symptoms 378 
occurring within known DM1 families, highlight the importance of awareness of variant 379 
repeats among clinical genetic services. The cases reported were identifiable from 380 
abnormal diagnostic TP-PCR traces, although clinicians should also be mindful of the 381 
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possibility of false negative results on TP-PCR, particularly if undertaken in a single 382 
direction. Furthermore, there are implications for genetic counselling, since progression 383 
of disease and transmission of the expanded allele to offspring may be significantly 384 
different in those with variant repeats compared to pure CTG repeats, although accurate 385 
predictions cannot be made based on current data. Observations to date also suggest that 386 
screening for variant repeats would be an important component of patient stratification 387 
for clinical trials, since such individuals may be statistical outliers in terms of disease 388 
severity and thus could confound interpretation of trial data, especially where cohorts 389 
are small.  390 
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Titles and Legends to Figures 522 
Figure 1. One member of each family has AciI-sensitive variant repeats. Each 523 
family tree shows only affected individuals; the proband is marked with an arrow. The 524 
individuals suspected to have variant repeat interruptions are shown in grey. ID = 525 
patient code, Age = age at sampling. The panels show small pool PCR products from 526 
500 pg template DNA, undigested (-) or digested with the restriction enzyme AciI that 527 
recognises CCG or CGG variant repeats (+) and Southern blotted. The expanded alleles 528 
from DMGV14, 182 and 15 each contain AciI-sensitive variant repeats and have been 529 
digested; all other expanded alleles remain uncut. The non-disease associated allele (N), 530 
and molecular weight marker (bp) are indicated. The equivalent number of triplet 531 
repeats in undigested fragments (rpts) for each molecular weight marker was 532 
determined by subtracting the length of the sequence flanking the repeat (106 bp), and 533 
dividing by three.  534 
 535 
Figure 2. Expanded alleles containing variant repeats are stabilised in blood DNA, 536 
but not in the germline. A. The panels on the left show small pool PCR products from 537 
300 pg template DNA from the three patients with variant repeats. The panels on the 538 
right show small pool PCR products from five patients without known variant repeats 539 
and with broadly similar ages and repeat lengths. The white dashed lines show the 540 
estimated progenitor allele length and the mode. The expanded alleles from the three 541 
patients with variant repeats are stabilised compared to those without. ID = patient code, 542 
Age = age at sampling. The non-disease causing allele (N), molecular weight marker 543 
(bp) and the equivalent number of triplet repeats (rpts) are indicated. B. The panels 544 
show small pool PCR products from 500 pg genomic DNA (DMGV14, CVS), or an 545 
 23 
empirically determined equivalent of whole genome amplified DNA, undigested (-) or 546 
digested with the restriction enzyme AciI that recognises CCG or CGG variant repeats 547 
(+) and Southern blotted. CVS = chorionic villus sample from an affected pregnancy, 548 
E1 to E7 = whole genome amplified samples from seven embryos generated by IVF. 549 
DNA was amplified from blastomere (blast) or trophectoderm (troph). The non-disease 550 
causing allele (N), size in base pairs (bp) and the number of triplet repeats in undigested 551 
fragments (rpts) are indicated. 552 
Figure 3. PacBio sequencing confirms that CCG variant repeats have arisen de 553 
novo in each family. For each family, the top panel shows the 3’-end of PacBio 554 
sequence reads for both father and child, zoomed-out (left) and zoomed-in (right). 555 
Mismatches compared to the reference sequence (usually the C in a CCG repeat) appear 556 
black. The approximate number of reads in the zoomed-out panels is shown to the left 557 
of the top panel. The junction between the repeats and the 3’-flank, where a G 558 
nucleotide is frequently missing from the sequence reads, is marked ΔG. The distance in 559 
repeats (rpts) from the 3’-flank is marked below the zoomed-out panel showing reads 560 
from the individual with variant repeats. For each family, the schematic diagram below 561 
the sequence read panels shows the average allele structure determined by scoring reads 562 
from the individual with variant repeats. 563 
Figure 4. Single molecule PCR products from DMGV182 are always at least 564 
partially digested by AciI. The panels show single molecule PCR products from 565 
DMGV182 undigested (-) or digested with the restriction enzyme AciI that recognises 566 
CCG or CGG variant repeats (+) and Southern blotted. The pairs of panels on the left (1 567 
to 3) show examples of molecules that appear completely digested by AciI. The pairs of 568 
panels on the right (4 to 6) show examples of molecules only partially digested by AciI. 569 
 24 
The white arrows in the right-hand panel of each pair show the digestion product(s) that 570 
correspond to each PCR product. This contrasts with the PacBio sequencing data for the 571 
same sample, where 17% of CCS reads did not contain CCG variant repeats near the 3’-572 
end.  573 
Family	  
DMGV	  
ID 
Age	  at	  
last	  
review 
Self-­‐reported	  age	  
at	  symptom	  onset	  
MIRS Neuromuscular	  assessment 
Cardiac	  	  
abnormality 
Cataract	   Other	  diagnoses 
In	  full	  time	  
education	  or	  
employment? 
Age	  at	  DNA	  
sampling	  
(years)	  
Progenitor	  
allele	  length	  
(repeats)	  
Modal	  allele	  
size	  (repeats)	  
1	   14 33 Denies	  symptoms	   1 No	  clinically	  apparent	  weakness	  or	  
myotonia 
-­‐ - Hypothyroid	   Y	   25.5	   381	   418	  
1	   57 36 
 
5	   4 Marked	  facial	  weakness	  with	  ptosis.	  
Distal	  weakness	  with	  relative	  
sparing	  of	  deltoids.	  	  	  Grip	  myotonia.	  	  
Uses	  bilateral	  ankle	  foot	  orthoses.	   
-­‐ - Paraumbilical	  fistula	  
Horseshoe	  kidney	  
Malone	  procedure	  for	  faecal	  incontinence	  
N	   20.5	   597	   922	  
1	   165 62 28	   4 Dysarthria.	  	  Walks	  with	  a	  stick	  
indoors,	  wheelchair	  for	  outdoors	   
First	  degree	  heart	  
block 
+ Diverticulosis	  
Hypokalaemia	  
Ischaemic	  heart	  disease	  
Barrett’s	  oesophagus	  
N	   59	   383	   811	  
1	   83	   71	   38	   4	   Grip	  MRC	  grade	  2/5,	  proximal	  
power	  4/5	  
Implantable	  cardiac	  
defibrillator	  in	  situ	  
+ Seen	  by	  speech	  and	  language	  therapist	  for
	  swallowing	  issues	  
N	   46	   105	   131	  
2	   182	   37 Denies	  symptoms	   1	   No	  clinically	  apparent	  weakness	  or	  
myotonia.	  Mild	  masseter	  myotonia	  
and	  peripheral	  muscle	  membrane	  
irritability	  on	  EMG	  
-­‐ + Dermal	  fibrosis	  	   Y	   33.5	   293	   368	  
2	   184	   31 20	   2	   Walks	  independently.	  Grip	  
myotonia.	   -­‐ - Oligospermia	  Bowel	  symptoms	  with	  bacterial	  
overgrowth	  
Low	  grade	  neutropenia	  	  
Low	  immunoglobulin	  G	  
Recurrent	  pilomatrixoma	  
Y	   28	   288	   652	  
2	   206	   69 60	   2	   Walks	  independently,	  mild	  
myotonia	  only.	  Jaw	  weakness	   Electrical	  cardioversion	  for	  
atrial	  flutter	   
- Investigated	  for	  abnormal	  liver	  function	  
tests	  	  
Moderate	  pharyngeal	  dysphagia	  
Borderline	  hypercalcaemia	  
N	  (Retired)	   70	   90	   131	  
2	   242	   65 ND	   2	   Walks	  independently,	  no	  myotonia	   -­‐ - Osteopenia	  
Recurrent	  primary	  hyperparathyroidism	  
N	  (Retired)	   65	   80	   99	  
	  	  
Table	  1:	  Summary	  of	  clinical	  features	  in	  families	  1,	  2	  and	  3.	  	  Individuals	  found	  to	  carry	  variant	  repeat	  alleles	  are	  highlighted	  in	  grey.	  	  MIRS	  =	  Muscle	  Impairment	  Rating	  Scale;	  MRC	  =	  Medical	  Research	  Council;	  ND	  =	  no	  data,	  EMG	  =	  electromyography.	  	  
3	   15	   46	   Denies	  symptoms	   1	   No	  clinically	  apparent	  weakness	  or	  
myotonia	  
Mitral	  valve	  
replacement	  for	  
congenital	  heart	  
anomaly	  
- None	   Y	   39	   303	   379	  
3	   54	   43	   35	   4	   Bilateral	  ankle	  foot	  orthoses	  for	  
foot	  drop.	  Distal	  weakness	  with	  
poor	  grip	  strength,	  forearm	  
weakness	  and	  wasting	  with	  relative	  
sparing	  of	  deltoid.	  
-­‐	   - None	   N	   40	   146	   230	  
3	   234	   53	   ND	   ND	   Severe	  generalised	  muscle	  
weakness,	  marked	  grip	  and	  
percussion	  myotonia,	  bilateral	  
ptosis	  
ND	   ND Sudden	  death	  at	  age	  54	  secondary	  to	  
respiratory	  failure	  
ND	   ND	   496	   663	  
Table	  2:	  Somatic	  instability	  of	  repeat	  expansions	  with	  and	  without	  CCG	  variant	  repeat	  interruptions	  	   Patient	  ID	   Age	  at	  sampling	  (years)	   Variant	  repeats	   ePAL	  (repeats)	   Mode	  (repeats)	   ΔCTG	  DMGV14	   25.5	   Y	   381	   418	   37	  DMGV182	   33.5	   Y	   294	   359	   65	  DMGV15	   39	   Y	   327	   385	   58	  DMGV82	   28	   N	   337	   533	   196	  DMGV158	   33	   N	   277	   643	   366	  DMGV159	   21.5	   N	   346	   490	   144	  DMGV184	   28	   N	   308	   629	   321	  DMGV262	   34	   N	   304	   516	   212	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